Prey S, Paul C, Bronsard V, Puzenat E, Gourraud PA, Aractingi S, et al. Assessment of risk of psoriatic arthritis in patients with plaque psoriasis: a systematic review of the literature. J Eur Acad Dermatol Venereol. 2010;24(Suppl 2):31–5.
Huynh D, Kavanaugh A. Psoriatic arthritis: current therapy and future approaches. Rheumatology. 2015;54(1):20–8.
Lee S, Mendelsohn A, Sarnes E. The burden of psoriatic arthritis: a literature review from a global health systems perspective. P & T: a peer-reviewed journal for formulary management. 2010;35(12):680–9.
Cantini F, Niccoli L, Nannini C, Cassara E, Kaloudi O, Giulio Favalli E, et al. Tailored first-line biologic therapy in patients with rheumatoid arthritis, spondyloarthritis, and psoriatic arthritis. Semin Arthritis Rheum. 2016;45(5):519–32.
Gottlieb A, Korman NJ, Gordon KB, Feldman SR, Lebwohl M, Koo JY, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis: section 2. Psoriatic arthritis: overview and guidelines of care for treatment with an emphasis on the biologics. J Am Acad Dermatol. 2008;58(5):851–64.
Soriano ER, McHugh NJ. Therapies for peripheral joint disease in psoriatic arthritis. A systematic review. J Rheumatol. 2006;33(7):1422–30.
Gottlieb AB. Psoriasis - enhanced epidermal differentiation and reduced cell-mediated inflammation are unexpected outcomes. Dis Manag Clin Outcomes. 1998;1(6):195–202.
Gottlieb AB. Novel immunotherapies for psoriasis: clinical research delivers new hope for patients and scientific advances. The journal of investigative dermatology Symposium proceedings / the Society for Investigative Dermatology, Inc [and] European Society for Dermatological Research. 2004;9(1):79–83.
Gottlieb AB. Psoriasis: emerging therapeutic strategies. Nat Rev Drug Discov. 2005;4(1):19–34.
Lu G, Ades AE. Combination of direct and indirect evidence in mixed treatment comparisons. Stat Med. 2004;23(20):3105–24.
Dias S, Welton NJ, Sutton AJ, Ades A. NICE DSU Technical Support Document 1: Introduction to evidence synthesis for decision making. University of Sheffield, Decision Support Unit 2011:1-24.
Jansen JP, Fleurence R, Devine B, Itzler R, Barrett A, Hawkins N, et al. Interpreting indirect treatment comparisons and network meta-analysis for health-care decision making: report of the ISPOR task force on indirect treatment comparisons good research practices: part 1. Value Health. 2011;14(4):417–28.
Sutton A, Ades A, Cooper N, Abrams K. Use of indirect and mixed treatment comparisons for technology assessment. PharmacoEconomics. 2008;26(9):753–67.
Ritchlin CT, Kavanaugh A, Gladman DD, Mease PJ, Helliwell P, Boehncke WH, et al. Treatment recommendations for psoriatic arthritis. Ann Rheum Dis. 2009;68(9):1387–94.
Felson DT, Anderson JJ, Boers M, Bombardier C, Chernoff M, Fried B, et al. The American College of Rheumatology preliminary core set of disease activity measures for rheumatoid arthritis clinical trials. The committee on outcome measures in rheumatoid arthritis clinical trials. Arthritis Rheum. 1993;36(6):729–40.
Langley RG, Ellis CN. Evaluating psoriasis with psoriasis area and severity index, psoriasis global assessment, and lattice system Physician's global assessment. J Am Acad Dermatol. 2004;51(4):563–9.
Louden BA, Pearce DJ, Lang W, Feldman SR. A simplified psoriasis area severity index (SPASI) for rating psoriasis severity in clinic patients. Dermatol Online J. 2004;10(2):7.
Johnson & Johnson Health Care Systems Inc. Reimbursement Resources (Remicade) 2017 [cited 2017 May 8]. Available from: https://www.janssencarepath.com/hcp/remicade/reimbursement.
Feldman SR, Garton R, Averett W, Balkrishnan R, Vallee J. Strategy to manage the treatment of severe psoriasis: considerations of efficacy, safety and cost. Expert Opin Pharmacother. 2003;4(9):1525–33.
Signorovitch JE, Betts KA, Yan YS, LeReun C, Sundaram M, Wu EQ, et al. Comparative efficacy of biological treatments for moderate-to-severe psoriasis: a network meta-analysis adjusting for cross-trial differences in reference arm response. Br J Dermatol. 2015;172(2):504–12.
Mease PJ, Goffe BS, Metz J, VanderStoep A, Finck B, Burge DJ. Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trial. Lancet. 2000;356(9227):385–90.
Antoni CE, Kavanaugh A, Kirkham B, Tutuncu Z, Burmester GR, Schneider U, et al. Sustained benefits of infliximab therapy for dermatologic and articular manifestations of psoriatic arthritis: results from the infliximab multinational psoriatic arthritis controlled trial (IMPACT). Arthritis Rheum. 2005;52(4):1227–36.
Genovese MC, Mease PJ, Thomson GT, Kivitz AJ, Perdok RJ, Weinberg MA, et al. Safety and efficacy of adalimumab in treatment of patients with psoriatic arthritis who had failed disease modifying antirheumatic drug therapy. J Rheumatol. 2007;34(5):1040–50.
Gottlieb A, Menter A, Mendelsohn A, Shen YK, Li S, Guzzo C, et al. Ustekinumab, a human interleukin 12/23 monoclonal antibody, for psoriatic arthritis: randomised, double-blind, placebo-controlled, crossover trial. Lancet. 2009;373(9664):633–40.
Mease PJ, Kivitz AJ, Burch FX, Siegel EL, Cohen SB, Ory P, et al. Etanercept treatment of psoriatic arthritis: safety, efficacy, and effect on disease progression. Arthritis Rheum. 2004;50(7):2264–72.
Coates LC, Kavanaugh A, Ritchlin CT, Committee GTG. Systematic review of treatments for psoriatic arthritis: 2014 update for the GRAPPA. J Rheumatol. 2014;41(11):2273–6.
Kavanaugh AF, Ritchlin CT, Committee GTG. Systematic review of treatments for psoriatic arthritis: an evidence based approach and basis for treatment guidelines. J Rheumatol. 2006;33(7):1417–21.
Sampogna F, Tabolli S, Soderfeldt B, Axtelius B, Aparo U, Abeni D, et al. Measuring quality of life of patients with different clinical types of psoriasis using the SF-36. Br J Dermatol. 2006;154(5):844–9.
Cawson MR, Mitchell SA, Knight C, Wildey H, Spurden D, Bird A, et al. Systematic review, network meta-analysis and economic evaluation of biological therapy for the management of active psoriatic arthritis. BMC Musculoskelet Disord. 2014;15:26.
Lubrano E, Spadaro A. Pharmacoeconomic burden in the treatment of psoriatic arthritis: from systematic reviews to real clinical practice studies. BMC Musculoskelet Disord. 2014;15:25.
Thorlund K, Druyts E, Avina-Zubieta JA, Mills EJ. Anti-tumor necrosis factor (TNF) drugs for the treatment of psoriatic arthritis: an indirect comparison meta-analysis. Biologics. 2012;6:417–27.
McInnes IB, Nash P, Ritchlin C, Thom H, Kanters S, Palaka E, et al. THU0437 Secukinumab for the treatment of psoriatic arthritis: comparative effectiveness results versus licensed biologics and Apremilast from a network meta-analysis. Ann Rheum Dis. 2016;75(Suppl 2):348–9.
Dongze W, Jiang Y, Tam L. FRI0523 short-term efficacy and safety of new biological agents targeting the IL-6, IL-12/23 and IL-17 pathways for active psoriatic arthritis: a network meta-analysis of randomised controlled trials: BMJ Publishing Group Ltd; 2017.
Mease PJ, Gladman DD, Ritchlin CT, Ruderman EM, Steinfeld SD, Choy EH, et al. Adalimumab for the treatment of patients with moderately to severely active psoriatic arthritis: results of a double-blind, randomized, placebo-controlled trial. Arthritis Rheum. 2005;52(10):3279–89.
Ungprasert P, Thongprayoon C, Davis JM 3rd. Indirect comparisons of the efficacy of biological agents in patients with psoriatic arthritis with an inadequate response to traditional disease-modifying anti-rheumatic drugs or to non-steroidal anti-inflammatory drugs: a meta-analysis. Semin Arthritis Rheum. 2016;45(4):428–38.
Yang TS, Chi CC, Wang SH, Lin JC, Lin KM. Cost‐efficacy of biologic therapies for psoriatic arthritis from the perspective of the Taiwanese healthcare system. International journal of rheumatic diseases. 2016;19(10):1002–9.
Singh JA, Christensen R, Wells GA, Suarez-Almazor ME, Buchbinder R, Lopez-Olivo MA, et al. A network meta-analysis of randomized controlled trials of biologics for rheumatoid arthritis: a Cochrane overview. Can Med Assoc J. 2009;181(11):787–96.
Wandel S, Juni P, Tendal B, Nuesch E, Villiger PM, Welton NJ, et al. Effects of glucosamine, chondroitin, or placebo in patients with osteoarthritis of hip or knee: network meta-analysis. BMJ. 2010;341:c4675.
Kavanaugh A, Mease PJ, Gomez-Reino JJ, Adebajo AO, Wollenhaupt J, Gladman DD, et al. Treatment of psoriatic arthritis in a phase 3 randomised, placebo-controlled trial with apremilast, an oral phosphodiesterase 4 inhibitor. Ann Rheum Dis. 2014;73(6):1020–6.
Cutolo M, Myerson GE, Fleischmann RM, Liote F, Diaz-Gonzalez F, Van den Bosch F, et al. Long-term (52-week) results of a phase 3, randomized, controlled trial of Apremilast, an oral Phosphodiesterase 4 inhibitor, in patients with psoriatic arthritis (PALACE 2). Arthritis Rheum. 2013;65(Suppl 10):815.
Edwards CJ, Blanco FJ, Crowley J, Hu C, Stevens RM, Birbara CA. Long-term 52-week results of Palace 3, a phase 3, randomized, controlled trial of Apremilast, an oral Phosphodiesterase 4 inhibitor, in patients with psoriatic arthritis and current skin involvement. Arthritis Rheum. 2014;53(Suppl 1):138–9.
Birbara C, Blanco FJ, Crowley JJ, Hu C, Stevens R, Edwards CJ. Efficacy of apremilast, an oral phosphodiesterase 4 inhibitor, on physical function and pain in patients with psoriatic arthritis, including current skin involvement: results of a phase 3, randomized, controlled trial. Ann Rheum Dis. 2013;72(Suppl 3):678.
National Institutes of Health. PALACE 3: Efficacy and Safety Study of Apremilast to Treat Active Psoriatic Arthritis 2015 [cited 2015 August 3]. Available from: https://clinicaltrials.gov/ct2/show/results/NCT01212770.
Wells AF, Edwards CJ, Adebajo AO, Kivitz AJ, Bird P, Shah K, et al., editors. Apremilast in the treatment of DMARD-naïve psoriatic arthritis patients: results of a phase 3 randomized, controlled trial (PALACE 4). 2013 ACR/ARHP annual meeting late-breaking abstracts; 2013 October 25–30, 2013; San Diego, CA.
ClinicalTrials.gov. Efficacy and Safety Study of Apremilast to Treat Active Psoriatic Arthritis (PsA) (PALACE4) 2014 [cited 2015 July 6]. Available from: https://clinicaltrials.gov/ct2/show/results/NCT01307423.
Mease PJ, Fleischmann R, Deodhar AA, Wollenhaupt J, Khraishi M, Kielar D, et al. Effect of certolizumab pegol on signs and symptoms in patients with psoriatic arthritis: 24-week results of a phase 3 double-blind randomised placebo-controlled study (RAPID-PsA). Ann Rheum Dis. 2014;73(1):48–55.
Kavanaugh A, McInnes I, Mease P, Krueger GG, Gladman D, Gomez-Reino J, et al. Golimumab, a new human tumor necrosis factor alpha antibody, administered every four weeks as a subcutaneous injection in psoriatic arthritis: twenty-four-week efficacy and safety results of a randomized, placebo-controlled study. Arthritis Rheum. 2009;60(4):976–86.
Antoni C, Krueger GG, de Vlam K, Birbara C, Beutler A, Guzzo C, et al. Infliximab improves signs and symptoms of psoriatic arthritis: results of the IMPACT 2 trial. Ann Rheum Dis. 2005;64(8):1150–7.
Mease PJ, McInnes IB, Kirkham B, Kavanaugh A, Rahman P, van der Heijde D, et al. Secukinumab inhibition of interleukin-17A in patients with psoriatic arthritis. N Engl J Med. 2015;373(14):1329–39.
McInnes IB, Mease PJ, Kirkham B, Kavanaugh A, Ritchlin CT, Rahman P, et al. Secukinumab, a human anti-interleukin-17A monoclonal antibody, in patients with psoriatic arthritis (FUTURE 2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2015;386(9999):1137–46.
McInnes IB, Kavanaugh A, Gottlieb AB, Puig L, Rahman P, Ritchlin C, et al. Efficacy and safety of ustekinumab in patients with active psoriatic arthritis: 1 year results of the phase 3, multicentre, double-blind, placebo-controlled PSUMMIT 1 trial. Lancet. 2013;382(9894):780–9.
Ritchlin C, Rahman P, Kavanaugh A, McInnes IB, Puig L, Li S, et al. Efficacy and safety of the anti-IL-12/23 p40 monoclonal antibody, ustekinumab, in patients with active psoriatic arthritis despite conventional non-biological and biological anti-tumour necrosis factor therapy: 6-month and 1-year results of the phase 3, multicentre, double-blind, placebo-controlled, randomised PSUMMIT 2 trial. Ann Rheum Dis. 2014;73(6):990–9.